Procyte 1994 — GHK-Cu Phase 3 Failure

October 1, 1994

Procyte Corp

Summary

Despite success in prior trials, GHK-Cu failed to prove more successful than placebo in 511-patient Phase 3 trial. Drug was safe but not efficacious. ProCyte later obtained FDA approval as Class I medical device.

Study Details

Study Design

Phase 3 randomized placebo-controlled trial

Indication

Wound healing

Intervention

Topical GHK-Cu

Species

Human

Sample Size

511 subjects